A Danish study1 in JI showed that the serum titer of anti-SARS-CoV-2 IgG, IgA and IgM antibodies in COVID-19 patients correlated with disease severity. “…Abs toward SARS-CoV-2 represent a double-edged sword…” In a Turkish study2 (also published in JI) of recovered COVID-19 patients, 20% did not have significant levels of SARS-CoV-2 neutralizing antibodies. This cohort […]

Johns Hopkins researchers used mouse ex vivo K14+ breast cancer organoid model to study the effect of tumor exposure to NK cells. teNK cells were found to lose cytotoxicity and to promote metastesis. This effect could be overcome by blockade with anti-TIGIT or anti-KRLG antibodies, both of which are promising immune checkpoints for Cancer therapy.

A 195-participant-study found that this drug prolonged survival and lessened inflammation in patients with severe Covid-19. “Repurposed Tocilizumab in Patients with Severe COVID-19” Jianbo Tian, Huilan Zhang , et al. (Dec 9, 2020) J Immunol ji2000981. doi: 10.4049/jimmunol.2000981.

Nasal spray contains a cholesterol linked lipopeptide which binds to the S2 region of SARS-CO-V2 spike in proximity to the HR2 domain. This prevents it from contracting towards the HR1 domain and therby inhibits cell fusion and infection. “Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets” Rory D. de Vries, Matteo Porotto,

anti-CD137 (4-1BB) agonistic mAb alone improves tumor infiltration and anti-tumor response in mice. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells” Patrick Innamarato, Shari Pilon-Thomas, et al. (Oct 2020) J Immunol October 5, 2020, ji2000759; DOI: https://doi.org/10.4049/jimmunol.2000759. Related Ancell Products anti-human CD137 mAb clone 4B4-1    

CoVix SerotopeTM ELISA plate assay to dectect human antibodies to SARS-CoV-2 (COVID-19) now available from InCepix. For Research Use Only!   Please inquire: info@incepix.com phone: (651) 560-2015

Ancell Corporation will continue to supply our important Human Immunology research reagents to the research community as it endeavors to combat the spread of and develop a useful vaccine to the newly discovered deadly coronavirus (Covid-19). Ancell Corporation provides useful tools that allow research scientists to understand how this virus attacks the human immune system.

“A novel and potent brain penetrant inhibitor of extracellular vesicle release” Camilo Rojas, Barbara Slusher, et al. 2019 Brit J Pharmacology 176: 3857-70. Doi: 10.1111/bph.14789. Using high throughput screening of 365,000 compounds, this research group from Johns Hopkins identified “PDDC”, a compound which penetrated brain tissue and inhibited release of murine astrocyte-derived EVs. Ancell anti-human

Check out the exciting new EVix extracellular vesicle research tools from InCepix.com!

Visit Ancell at the 2019 Autumn Immunology Conference at the Downtown Marriott Hotel in Chicago.  We’ll be exhibiting at booth T3  Sat Nov 23 through Sun Nov 24th .